The Delhi High Court has refused to stay the Centre’s notification which has accorded permission to conduct the Phase II/III clinical trial of Covaxin in the age group 2 to 18 years to its manufacturer Bharat Biotech Ltd.
However, the court issued notice to the Centre and Bharat Biotech to file their reply on a PIL against Covaxin’s clinical trials for age group 2 to 18.
Source: ILNS